Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)-Reference-Cited by-同舟云学术

Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Published:2015-02-09 Issue:6 Volume:58 Page:2609-2622
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hughes Adam D.¹,Chen Yan¹,Hegde Sharath S.¹,Jasper Jeffrey R.¹,Jaw-Tsai Sarah¹,Lee Tae-Weon¹,McNamara Alexander¹,Pulido-Rios M. Teresa¹,Steinfeld Tod¹,Mammen Mathai¹

Affiliation:

1. Departments of †Medicinal Chemistry, ‡Pharmacology, §Drug Metabolism and Pharmacokinetics, and ∥Molecular and Cellular Biology, Theravance Biopharma, Inc., 901 Gateway Boulevard, South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm501915g

Reference32 articles.

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

2. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs

3. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

4. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

5. For example, Prosonix,http://www.prosonix.co.uk/; Pearl Therapeutics,http://www.pearltherapeutics.com/; and Pulmatrix,http://www.pulmatrix.com/(all accessed February 2014) .

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β₂ Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases;Journal of Medicinal Chemistry;2024-06-10

2. Medicinal Polypharmacology in the Clinic – Translating the Polypharmacolome into Therapeutic Benefit;Pharmaceutical Research;2024-02-16

3. Synthesis, Spectroscopic, and Thermal Analyses of 2-Oxo-1,2-dihydroquinolin-8-yl 4-chlorobenzoate;Molbank;2023-06-19

4. 2-Phenethylamines in Medicinal Chemistry: A Review;Molecules;2023-01-14

5. The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β2 Adrenergic Receptor Agonist Navafenterol in Human Small Airways;Cells;2023-01-06